ReviewRSC advances2022
Molybdenum disulfide (MoS
Review in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 51 citations in OpenAlex.
- Recent advancements in visible light-induced, vitamin-catalysed chemical transformations.RSC advances · 2026Review
- Alloying Engineering of Defective Molybdenum Sulfide Basal Planes for Enhanced Borrowing Hydrogen Activity in the Thioetherification of Alcohols.ChemSusChem · 2025Article
- Molybdenum Disulfide-Based Catalysts in Organic Synthesis: State of the Art, Open Issues, and Future Perspectives.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Review
- Novel applications of photobiocatalysts in chemical transformations.RSC advances · 2024Review
- Visible-light acridinium-based organophotoredox catalysis in late-stage synthetic applications.RSC advances · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photoredox catalysis has been explored for chemical reactions by irradiation of photoactive catalysts with visible light, under mild and environmentally benign conditions. Furthermore, this methodology permits the activation of abundant chemicals into valuable products through novel mechanisms that are otherwise inaccessible. In this context, MoS
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.